Ptc Therapeutics Cmn (PTCT) 7.24 $PTCT New Analyses from

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 1:09 AM

Ptc Therapeutics Cmn (PTCT) 7.24 $PTCT

New Analyses from Phase 3 Study 009 of Translarna(TM) (ataluren) in Patients with Cystic Fibrosis Presented at 39th European Cystic Fibrosis Conference
PR Newswire - Fri Jun 10, 9:30AM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that new analyses from the company's previous Phase 3, double-blind, placebo-controlled, 48-week 009 trial of Translarna(TM) (ataluren) for the treatment of nonsense mutation cystic fibrosis (caused by at least one nonsense mutation) are being presented at the 39th European Cystic Fibrosis Conference, June 8-11, 2016, in Basel, Switzerland.
PTCT: 7.24 (-0.30)

PTC Therapeutics Announces Winners of the Global Cystic Fibrosis Patient Group Awards
PR Newswire - Mon May 16, 7:00AM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's global STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment) program, designed to support nonprofit organizations serving the cystic fibrosis (CF) community. The announcement coincides with National Cystic Fibrosis Awareness Month celebrated throughout the month of May.
PTCT: 7.24 (-0.30)

PTC Therapeutics reports 1Q loss
Automated Insights - Thu May 05, 5:06PM CDT
SOUTH PLAINFIELD, N.J. (AP) _ PTC Therapeutics Inc. (PTCT) on Thursday reported a loss of $41.2 million in its first quarter.
PTCT: 7.24 (-0.30)

PTC Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Thu May 05, 3:01PM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2016.
PTCT: 7.24 (-0.30)

DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of PTC Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 2, 2016 - PTCT
PR Newswire - Mon May 02, 10:25AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
PTCT: 7.24 (-0.30)

PTC 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against PTC Therapeutics, Inc. - PTCT
GlobeNewswire - Fri Apr 29, 9:07PM CDT
Kahn Swick & Foti, LLC ("KSF"

and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until May 2, 2016 to file lead plaintiff applications in a securities class action lawsuit against PTC Therapeutics, Inc. (Nasdaq

TCT). Investor losses must relate to purchases of the Company's securities between May 6, 2014 and February 29, 2016. This action is pending in the United States District Court for the District of New Jersey.
PTCT: 7.24 (-0.30)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PTC Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - PTCT
ACCESSWIRE - Fri Apr 29, 6:08PM CDT
NEW YORK, NY / ACCESSWIRE / April 29, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against PTC Therapeutics, Inc. ("PTC Therapeutics" or the "Company"

(NASDAQ: PTCT) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons or entities who purchased PTC Therapeutics securities between May 6, 2014 and February 23, 2016 inclusive (the "Class Period"

. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act"

.
PTCT: 7.24 (-0.30)

ALERT: Rosen Law Firm Reminds PTC Therapeutics, Inc. Investors of Important May 2 Deadline in Class Action - PTCT
GlobeNewswire - Thu Apr 28, 5:04PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of PTC Therapeutics, Inc. securities (NASDAQ

TCT) from May 6, 2014 through February 23, 2016, all dates inclusive (the "Class Period"

of the important May 2, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for PTC Therapeutics investors under the federal securities laws.
PTCT: 7.24 (-0.30)

Final Reminder for PTC Therapeutics, Inc. Shareholders - May 2, 2016 Deadline
ACCESSWIRE - Thu Apr 28, 3:42PM CDT
RADNOR, PA / ACCESSWIRE / April 28, 2016 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a shareholder class action lawsuit has been filed against PTC Therapeutics, Inc. (Nasdaq: PTCT) ("PTC" or the "Company"

on behalf of purchasers of the Company's securities between May 6, 2014 and February 29, 2016, inclusive (the "Class Period"

.
PTCT: 7.24 (-0.30)

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Class Action Involving PTC Therapeutics, Inc. and a Lead Plaintiff Deadline of May 2, 2016 - PTCT
GlobeNewswire - Thu Apr 28, 11:55AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased PTC Therapeutics, Inc. (NASDAQ

TCT) securities between May 7, 2014 and February 29, 2016.
PTCT: 7.24 (-0.30)

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of PTC Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 2, 2016 - PTCT
GlobeNewswire - Wed Apr 27, 11:19AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
PTCT: 7.24 (-0.30)

PTC Therapeutics Appoints Dr. Tuyen Ong as Chief Medical Officer
PR Newswire - Tue Apr 26, 3:01PM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Tuyen Ong, M.D. has been promoted to Chief Medical Officer. Dr. Ong joined PTC in 2014 as the Senior Vice President, Head of Clinical Development and Translational Research. He succeeds Robert J. Spiegel M.D., FACP, who has served as PTC's Chief Medical Officer since 2011. Dr. Spiegel will remain active in a consulting role, continuing to support PTC's development programs and its global clinical and regulatory activities.
PTCT: 7.24 (-0.30)

Deadline Alert: Law Offices of Howard G. Smith Reminds PTC Therapeutics, Inc. Investors of May 2 Deadline
BusinessWire - Tue Apr 26, 12:53PM CDT
Law Offices of Howard G. Smith reminds investors of the upcoming May 2, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased PTC Therapeutics, Inc. ("PTC" or the "Company"

(NASDAQ: PTCT) securities between May 6, 2014 and February 29, 2016, inclusive (the "Class Period"

. PTC investors have until May 2, 2016 to file a lead plaintiff motion.
PTCT: 7.24 (-0.30)

Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 5.40 (-0.09), EBIO: 1.87 (+0.19), PTCT: 7.24 (-0.30), PETX: 6.70 (-0.40), ARRY: 3.51 (-0.01)

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire - Fri Apr 22, 6:23PM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 22, 2016 it approved non-statutory stock options to purchase an aggregate of 26,000 shares of its common stock to 4 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hires' employment compensation.
PTCT: 7.24 (-0.30)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of PTC Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 2, 2016 - PTCT
BusinessWire - Fri Apr 22, 9:23AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
PTCT: 7.24 (-0.30)

PTC Therapeutics to Host Conference Call to Discuss First Quarter Financial Results
PR Newswire - Thu Apr 21, 3:30PM CDT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter financial results and provide an update on the company's business and outlook on Thursday, May 5, 2016 at 4:30 p.m. (ET) after the closing of the market.
PTCT: 7.24 (-0.30)

EXPANDED CLASS PERIOD: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against PTC Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm
BusinessWire - Wed Apr 20, 7:19PM CDT
Khang & Khang LLP (the "Firm"

announces that a class action lawsuit has been filed against PTC Therapeutics, Inc. ("PTC Therapeutics" or the "Company"

(Nasdaq: PTCT). Investors who purchased or otherwise acquired shares between May 6, 2014 and February 29, 2016, inclusive (the "Class Period"

, are encouraged to contact the Firm prior to the May 2, 2016, lead plaintiff motion deadline.
PTCT: 7.24 (-0.30)

Kessler Topaz Meltzer & Check, LLP Reminds PTC Therapeutics, Inc. Shareholders of Lead Plaintiff Deadline in Class Action Lawsuit - PTCT
ACCESSWIRE - Wed Apr 20, 8:55AM CDT
RADNOR, PA / ACCESSWIRE / April 20, 2016 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds PTC Therapeutics, Inc. (Nasdaq: PTCT) ("PTC" or the "Company"

shareholders that a class action lawsuit has been filed on behalf of purchasers of the Company's securities between May 6, 2014 and February 29, 2016, inclusive (the "Class Period"

.
PTCT: 7.24 (-0.30)

EXPANDED CLASS PERIOD: Lundin Law PC Announces Securities Class Action Lawsuit against PTC Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
BusinessWire - Tue Apr 19, 6:53PM CDT
Lundin Law PC announces a class action lawsuit has been filed against PTC Therapeutics, Inc. ("PTC Therapeutics" or the "Company"

(Nasdaq: PTCT) concerning possible violations of federal securities laws between May 6, 2014 and February 29, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the May 6, 2016, lead plaintiff motion deadline.
PTCT: 7.24 (-0.30)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rain Agent Vaults: Revolutionizing Payments with AI

Innovative Payments with AI Power Alright, folks, Rain's gone and done something that's probably going to shake things up in the payments world—'cause they've given AI agents the ability to handle money like never before. We're not just talking about some run-of-the-mill integration here. This is a genuine game changer, promising to make agents as financially savvy as...

ProBio, AbTis Forge Bond for Next-Gen Oncology ADCs

Deal or No Deal: ProBio's New Licensing Agreement In the ever-evolving realm of biopharmaceuticals, ProBio's recent handshake with South Korea's AbTis is stirring the pot. The shot-callers at ProBio are passing the baton to AbTis, giving them a crack at developing a thumping new therapeutic antibody asset aimed squarely at oncology targets. Pretty slick move if you ask...

Alogent's Unify Snags Award for Innovation and Impact

Innovation That Captures Attention Alogent sure did grab the spotlight with their Unify platform walking away with a Credit Union Times Luminaries Award. The name of the game here is deposit processing innovation—the kind of buzz that turns heads in the banking world. This recognition isn't just another plaque for the lobby; it's a testament to a significant stamp on...

Sokolove Law Wins $28.8M Verdict for Misdiagnosis Case

Jury Awards $28.8 Million in Misdiagnosis Case Well, here's a tale that's bound to ruffle some feathers in the medical community—$28.8 million tossed on the table because an emergency room missed a life-threatening aortic aneurysm. For the uninitiated, this isn't just chump change; it's the cost of dropping the ball when the stakes are as high as a human life. A jury in...

FirstDigital Expands Fiber Network in Utah and Arizona

Weaving a Web of Connectivity Let's talk about FirstDigital putting its shoulder to the wheel in Utah and Arizona. They're expanding their redundant fiber network to rope in more businesses under their umbrella of connectivity. This ain't just another dry IT endeavor—it's about building a safety net for our ever-connected world. The Stakes of Network Disruption You know...

Jubilant Eyes MPN Breakthrough with JBI-802 Data at ASH

Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...

Alyssa Bunch: Big Moves in Tennessee Real Estate

Navigating the Tennessee Real Estate Maze If you're talking about where the real estate action happens in Tennessee, you'd better mention Alyssa Bunch, the Vanderbilt-educated dynamo who turns the unforsale into the must-buy. Most of the deals she orchestrates are invisible to the public eye until they're all but written in ink and ready to reshape landscapes—or, more...

Bakersfield Sees Spike in Crashes Post Time Change

Evening Darkness and Safety Concerns Folks, it seems Bakersfield streets transform into a battlefield once the clock falls back. With darkness creeping in earlier, those evening hours right after the time change see a sobering uptick in accidents. According to an analysis by Chain | Cohn | Clark, pedestrian and bicyclist crashes from 5 to 7 p.m. double. It's not just...

IASO Bio's In Vivo CAR-T: A Game Changer for Oncology?

You ever feel like you're watching history happen right in front of you? That's the vibe with IASO Bio's latest move in the realm of oncology. This outfit just scored a major victory, getting China's NMPA and the U.S. FDA to greenlight their IASO208, a CD20-targeting in vivo CAR-T therapy. It's not every day you see a company land dual regulatory nods like...

Zephyr's Alto Hood: Redefining Kitchen Versatility

An Artist in the Kitchen Who knew a kitchen hood could be a canvas, right? Zephyr, always a punch above the ordinary in kitchen design, has pulled another rabbit out of their hat with the Alto Wall Custom Hood. Forget blending in; this piece is about standing out and shouting style—all while keeping your cooking area fresh. Options Galore The Alto Hood isn't about...